Recursion Pharmaceuticals Announces Appointment of Vicki Goodman, M.D., as Incoming Chief Medical Officer

Key Points from the Announcement

• Leadership Transition: Recursion Pharmaceuticals (NASDAQ: RXRX) has named Vicki Goodman, M.D., as its new Chief Medical Officer, effective April 6, 2026. Dr. Goodman succeeds David Mauro, M.D., Ph.D., who is transitioning out after approximately three years in the role.
• Strategic Timing: The leadership change comes at a pivotal moment for Recursion, as the company advances its clinical pipeline and prepares for key clinical and regulatory milestones. These milestones are consistent with previously communicated expectations.
• Dr. Goodman’s Unique Qualifications: Goodman brings over two decades of experience in oncology drug development and medical leadership, with executive roles spanning both biotech and large pharma. Her expertise includes clinical practice, FDA review experience, and leading clinical development of major oncology assets.

Details of Dr. Goodman’s Experience and Impact

• Recent Positions: Most recently, Dr. Goodman served as Chief Medical Officer of Mural Oncology, where she built and led the development organization and advanced a portfolio of novel cytokine assets.
• Previous Leadership Roles: She was Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer at Exelixis, overseeing early- and late-stage clinical development, regulatory affairs, pharmacovigilance, and biometrics across a multi-asset pipeline.
• Big Pharma Experience: At Merck, Dr. Goodman served as Vice President of Clinical Research and Therapeutic Area Head of Late-Stage Oncology, overseeing the late-stage portfolio, including KEYTRUDA® (pembrolizumab) across multiple tumor types. At Bristol Myers Squibb, she led development for OPDIVO® (nivolumab) and YERVOY® (ipilimumab) in melanoma and genitourinary cancers.
• Early Career: At GlaxoSmithKline, she led the development of dabrafenib from early clinical expansion through regulatory approval and contributed to advancing multiple oncology assets.
• FDA and Medical Training: Goodman began her career as a Medical Officer in the U.S. FDA, holds an M.D. from Albert Einstein College of Medicine, and completed clinical training in internal medicine and hematology/oncology at the University of Michigan.

Remarks from Leadership

Najat Khan, Ph.D., CEO and President of Recursion, emphasized the value of Dr. Goodman’s experience, especially in late-stage clinical development, stating it will be “invaluable as we translate scientific insight into disciplined, high-quality programs and deliver differentiated medicines for patients.”

Dr. Goodman commented, “Recursion stands apart in the industry through its ambitious integration of scientific and technological rigor to reimagine how medicines are discovered and developed through the power of AI. I’m thrilled to join the company at such an important moment.”

Outgoing CMO David Mauro reflected on his tenure, expressing pride in Recursion’s achievements and optimism for the company’s future at the intersection of technology and drug development.

Important Information for Shareholders

• Potential Price Sensitivity: Leadership transitions, especially involving the Chief Medical Officer, are significant for clinical-stage biotech companies. Dr. Goodman’s extensive track record in advancing oncology assets and regulatory approvals may enhance investor confidence in Recursion’s ability to achieve upcoming clinical and regulatory milestones.
• Pipeline Progress: Recursion continues to advance its pipeline, including the ongoing progression of REC-4881 and other investigational medicines, which may be a catalyst for future share price movement.
• AI-Driven Platform: The company’s end-to-end AI-native drug discovery and development platform, Recursion OS, integrates biology, chemistry, and clinical development, positioning Recursion at the forefront of TechBio innovation.
• Global Presence: Recursion operates automated laboratories in Salt Lake City, Utah, and Milton Park, Oxfordshire, and maintains offices in New York, Montréal, and London, signifying its commitment to global talent and leadership in AI and scientific innovation.

Conclusion

This leadership appointment is a material event for shareholders, as Dr. Goodman’s arrival may accelerate Recursion’s clinical development and enhance the company’s prospects for successful regulatory approvals and commercialization. Her proven expertise in oncology, regulatory affairs, and clinical leadership is expected to bolster Recursion’s position as a leading TechBio company, potentially impacting future share value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. The information presented is based on public disclosures and may be subject to change.

View RECURSION PHARMACEUTICALS, INC. Historical chart here